Evaxion concludes subject dosing in Phase II trial of melanoma vaccine
Source: Clinical Trials Arena, January 2025
Evaxion Biotech has completed subject dosing in the Phase II trial of its personalised peptide-based cancer vaccine, EVX-01, for the treatment of advanced melanoma, also referred to as skin cancer.
The trial, which is evaluating the vaccine in conjunction with MSD’s Keytruda, is progressing and remains on course for a data readout in the second half of this year.
Subjects in the trial received a distinctly designed and manufactured vaccine depending on their biological factors, the company noted.